In this study (1998)(1999) 
Macrolides, especially the newer agents (azithromycin and clarithromycin) are used extensively for the treatment of respiratory infections due to their broad-spectrum activity against both typical and atypical respiratory pathogens (5, 25) . However, emergence of erythromycin resistance (Ery-R) in Streptococcus pneumoniae is a growing concern because of the importance of this pathogen in infections of the respiratory tract (6, 13, 15, 25) . Although the prevalence of resistant strains varies geographically and temporally, antimicrobial resistance is widespread (6, 9, 10, 26) . Macrolide resistance in S. pneumoniae has increased during the 1990s to the extent that over 30% of clinical isolates are now resistant in some communities (2, 3, 21, 23, 27) .
Macrolide resistance in S. pneumoniae may be encoded by the erm(B) gene, which reduces the binding affinity of all macrolides for the 23s rRNA (domain V) and leads to crossresistance to macrolides, lincosamides, and streptogramin B (MLS B ) (16, 19, 27) . Cross-resistance occurs as a result of methylation of the adenine residue (A2058) within the overlapping binding sites for the three chemically distinct antimicrobial classes (16, 21, 23, 27) . S. pneumoniae strains possessing the erm(B) gene have an MLS B phenotype and usually express high-level resistance (MIC for 90% of strains [MIC 90 ], Ն64 g/ml) to MLS B antibiotics (23, 27) . The second macrolide resistance mechanism in S. pneumoniae is the efflux of the antibiotic (22) . S. pneumoniae strains with this type of resistance mechanism are classified as possessing an M-phenotype. An efflux pump encoded by the mef(A) gene in S. pneumoniae pumps out 14-and 15-membered macrolides only (20; K. Gay and D. S. Stephens, Program Abstr. 40th Intersci. Conf. Antimicrob. Agents Chemother., 2000, abstr. 1929). S. pneumoniae with an M-phenotype express low-level resistance (MIC 90 , Յ4 g/ml) to macrolides but demonstrate no cross-resistance to lincosamides and streptogramin B (20, 22) .
The prevalence of the MLS B and M-phenotypes varies both geographically and temporally (9, 10, 13, 21 Ketolides are third-generation, semisynthetic macrolides derived from clarithromycin (12) . These 14-membered antibiotics are made by the replacement of the cladinose at C-3 with a keto group (12) . This semisynthetic alteration of the natural erythromycin A molecule renders the drug more stable in acidic environments and reduces the induction of MLS B resistance phenotype (7, 8, 12) . Ketolides have activity against a broad range of respiratory tract pathogens, including S. pneumoniae, Haemophilus influenzae, Moraxella catarrhalis, Mycoplasma species, Legionella species, and some anaerobic bacteria (4, 7, 12) . Previous work has demonstrated that ketolides are active against macrolide-resistant S. pneumoniae, whether possessing the erm(B) or mef(A) genotype (12) . Ketolides bind to domain II as well as domain V of 23s rRNA (13) . In addition to the additional ribosomal contact, the potency of ketolides may also be due to slow dissociation from the ribosome (11) . The purpose of this study was to determine the incidence of erm(B) and mef(A) among erythromycin-resistant S. pneumoniae isolated in Canada (1998 Canada ( -1999 during an ongoing national respiratory surveillance program. Second, the activity of telithromycin and ABT-773, two new ketolides, was assessed against erm(B) and mef(A) S. pneumoniae.
S. pneumoniae isolates were collected between 1998 and 1999 from an ongoing national surveillance study (Canadian
Respiratory Organism Susceptibility Study [CROSS] [28]).
Specifically, isolates were obtained from 23 medical centers in 9 of 10 Canadian provinces (26) . Consecutive isolates, one per patient, were collected from respiratory tract specimens only. Isolates were identified by conventional methodology and deemed to be respiratory pathogens by individual laboratory protocols. All isolates were shipped to a central laboratory (Health Sciences Centre, Winnipeg, Manitoba) on Amies charcoal swabs. The identity of each S. pneumoniae was confirmed by the central reference laboratory, and it was then stored in skim milk and stored at Ϫ80°C (26) .
Antibiotics for this study were supplied by the manufacturers: erythromycin (Hoechst Marion Rousell, Romainville, France), ABT-773 (Abbott, Abbott Park, Ill.), telithromycin (Hoechst Marion Rousell, Romainville, France) and clindamycin (Pharmacia and Upjohn, Mich.). Antibiotics were reconstituted according to National Committee for Clinical Laboratory Standards (NCCLS) guidelines (18) . Susceptibility to erythromycin, clindamycin, telithromycin, and ABT-773 was determined using the NCCLS M7-A4 broth microdilution method (20) . Each final-panel well volume was 100 l, with a bacterial inoculum of 5 ϫ 10 5 CFU/ml. Panels were read following 20 to 24 h of incubation at 35°C in ambient air. The MIC was defined as the lowest concentration of antibiotic inhibiting visible growth. Colony counts were performed periodically to confirm inocula.
S. pneumoniae cultures were grown overnight on Trypticase soy agar with 5% sheep blood, and two to five colonies were resuspended in 1 ml of sterile saline. Following centrifugation at 13,000 rpm for 10 min, supernatants were removed, and the resulting bacterial pellet was resuspended in 300 l of lysis buffer containing 0.1 M NaOH, 2.0 M NaCl, and 0.5% sodium dodecyl sulfate (SDS). Cell suspensions were then boiled for 15 min, and 200 l of 0.1 M Tris-HCl (pH 8.0) was added. For extraction of genomic DNA, 500 l of phenol-chloroformisoamyl alcohol (25:24:1) was added, and the mixture was centrifuged at 13,000 rpm for 10 min; 1 ml of cold (Ϫ20°C) anhydrous alcohol was then added, and DNA was precipitated at Ϫ80°C for a minimum of 30 min. The precipitated DNA was collected by centrifugation at 13,000 rpm for 15 min at 4°C, and the pellets were allowed to air dry for no less than half an hour. Pellets containing the purified DNA were subsequently resuspended in sterile distilled water and used as the DNA template (26) .
DNA was amplified in a total volume of 50 l containing 5 l of template DNA, 5 l of 40 mM MgCl 2 -10ϫ PCR buffer, 1.25 mM each of dCTP, dGTP, dATP, and dTTP (Amersham Pharmacia Biotech), 100 mM each primer (Gibco-BRL), 2.5 U of Taq DNA polymerase (Amersham Pharmacia Biotech), and 30.5 l of sterile distilled water. Primers used for amplification of erm(B) and mef(A) were 5Ј-GAAAAGGTACTAAACCAA ATA-3Ј and 5Ј-AGTAACGGTACTTAAATTGTTTAC-3Ј (PCR product, 616 bp) and 5Ј-ACTATCATTAATCACTAG TGC-3Ј and 5Ј-TTCTTCTGGTACTAAAAGTGG-3Ј (PCR product, 346 bp), respectively (16) . Amplification of erm(B) and mef(A) was performed using a Perkin-Elmer GeneAmp PCR system 9700 and consisted of initial denaturation at 95°C for 2 min, 30 cycles at 95, 52, and 72°C for 1 min each, and a final extension at 72°C for 10 min. Amplified DNA fragments were analyzed by electrophoresis through 2% agarose gels containing ethidium bromide and visualized under UV transillumination. S. pneumoniae ATCC 49619 and a mef(A) or erm(B) strain were consistently included as negative and positive controls, respectively.
An ongoing national surveillance study representing all regions in Canada (CROSS) was initiated in 1997 (26) . In 1998-1999, 2,688 S. pneumoniae isolates from respiratory tract specimens were prospectively collected from 23 different medical centers throughout Canada, and 215 of these isolates were identified as being resistant to erythromycin. Thus, the national macrolide resistance rate in S. pneumoniae in Canada was approximately 8%. The incidence of macrolide-resistant S. pneumoniae from 1997 to 2000 has consistently remained at approximately 8% over the 3 years of the study (26; Karlowsky et al., abstr. 7.11). The 215 macrolide-resistant S. pneumoniae isolates were screened for the presence of mef(A) and erm(B), the two major macrolide resistance genes described in S. pneumoniae. The results of the PCR amplification studies for mef(A) and erm(B) are displayed in Table 1 .
The quality control strains tested [ATCC 49619, mef(A) positive, and erm(B) positive] were in control (data not shown). As shown in Table 1 , 48.8% of macrolide-resistant S. pneumoniae were PCR positive for mef(A), demonstrating the presence of a macrolide efflux pump. The erythromycin MICs for these strains ranged from 1 to Ն64 g/ml; however, the majority of these isolates had erythromycin MICs of 1 to 4 g/ml (see Table 3 ). None of the mef(A)-positive strains were resistant to clindamycin, and 46.5% of all macrolide-resistant S. pneumoniae were PCR positive for erm (B) . Erythromycin MICs for erm(B)-positive strains ranged from 1 to Ն64 g/ml; however, the majority of the isolates demonstrated very high erythromycin MICs of Ն32 g/ml (See Table 3 ). The majority of erm(B)-positive S. pneumoniae were resistant to clindamycin. A small number (2.8%) of macrolide-resistant S. pneumoniae were erm(B) and mef(A). All of these strains had high MICs to erythromycin, and the majority were concomitantly resistant to clindamycin (Tables 2 and 3 ); 1.9% of strains were both mef(A) and erm(B) negative, generally displayed very low MICs to erythromycin, and were susceptible to clindamycin. Table 1 describes the susceptibility of macrolide-resistant S. pneumoniae to both telithromycin and ABT-773. As can be seen from Table 1 Table 3 describes the telithromycin and ABT-773 distributions with macrolide-susceptible and -resistant S. pneumoniae. As can be seen, the majority of telithromycin MICs against erm(B)-positive S. pneumoniae clustered between 0.004 and 0.008 g/ml. Telithromycin MICs for mef(A)-positive strains were more disparate, 0.004 to 0.06 g/ml (Table 3) Presently the prevalence of macrolide resistance in Canada is low at approximately 8%. Since 1997, in our ongoing national surveillance program, which assesses macrolide resistance in over 1,000 respiratory isolates of S. pneumoniae per year from all regions of Canada, macrolide resistance has been approximately 8% and appears to have remained stable over the last 3 years (26; Karlowsky et al., abstr. 7.11). The low and stable incidence of macrolide-resistant S. pneumoniae in Canada has occurred despite large increases (29.5% over 1995 to 1998) in macrolide use in all regions of Canada, especially with the new macrolides, such as azithromycin and clarithromycin (5) . Perhaps the reason why macrolide resistance is stable in Canada despite large increases in use of newer macrolides may be that total antibiotic use (total number of prescriptions for all antibiotics per year) is decreasing in Canada (14%) over the last 5 years (1995 to 1999) (G. G. Zhanel, A. Carrie, L. Hoban, K. Weiss, D. E. Low, and A. S. Gin, 40th ICAAC, p. 508).
Presently, 48.8% of macrolide-resistant S. pneumoniae in Canada harbor mef(A), while 46.5% of macrolide-resistant S. pneumoniae harbor erm(B). These data are consistent with previous Canadian and U.S. data and suggest that approximately 50% of macrolide-resistant S. pneumoniae possess a macrolide efflux pump and this has not changed over the last 7-year period (13, 21; Karlowsky et al., abstr. 7.11). The importance of knowing whether macrolide-resistant S. pneumoniae have mef(A) or erm(B) is that low-level macrolide resistance might be cured by drug concentrations that are clinically achievable in tissues (1) . On the other hand, strains demonstrating high MICs to erythromycin may lead to microbiological and clinical failure with macrolides in patients with community-acquired pneumonia (14) . In this study we demonstrated that both telithromycin and ABT-773 had excellent activity against macrolide-resistant S. pneumoniae possessing the mef(A) or erm(B) phenotype. In light of their excellent activity against macrolide-resistant S. pneumoniae, ketolides may be an attractive alternative for the treatment of respiratory tract infections caused by this important pathogen.
